Skyrizi is approved for moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. AbbVie said the annual wholesale cost for maintenance dosing of ...

Crohn's the third indication for Skyrizi after psoriasis and psoriatic arthritis ... The FDA is also reviewing a lower 180mg maintenance dose. Thomas Hudson, AbbVie's chief scientific officer ...

Novo Nordisk slashed its spending on TV ads for Wegovy by almost 24% between April and May, from $31.6 million to $24.1 ...

Bimekizumab use for 4 years among patients with plaque psoriasis is associated with sustained efficacy outcomes and no new safety signals.

May 27, 2025 — Researchers have found that central body fat, especially around the abdomen, is more strongly linked to psoriasis risk than total body fat, particularly in women. This link ...

He said reducing the steps to target dosing could help overcome clinical inertia. "In real-world practice, most patients never achieve the target doses of recommended heart failure medications ...

This study is the first randomized, double-blind, controlled Phase 3 clinical study evaluating biologics switching in psoriasis patients with prior ... with continued picankibart maintenance treatment ...

This study is the first randomized, double-blind, controlled Phase 3 clinical study evaluating biologics switching in psoriasis patients ... maintenance treatment dosing every 12 weeks.